NATERA INC

Explore how Natera’s Prospera cfDNA assay is set to transform kidney‑transplant monitoring in a groundbreaking Phase 3 study with Eledon, potentially reducing calcineurin use and improving long‑term graft outcomes.

Discover how a co‑founder’s insider sales at Natera (NTLA) signal strategic portfolio shifts and what they mean for investors in the high‑tech diagnostics market.

Discover how Natera’s board expansion, equity incentive plan boost and shareholder approvals reinforce governance, talent retention and investor confidence in biotech.

Corporate update: Natera, Inc. adds Thomas Lynch to its 12‑member board, details insider share sales, and confirms compliance with SEC filings.

Discover how Natera’s insider moves and CytoDyn partnership position it to capture the rising $35 billion oncology diagnostics market, boost growth, and attract strategic investors.

Analyze Natera’s 10 b5‑1 insider sales: how a 235,000‑share trade by co‑founder Sheena Jonathan and trust holdings affect pricing, liquidity, and investor confidence in the genomics market.

Explore how Natera’s insider‑sale of RSUs signals strong cash flow and the company’s strategy to invest in next‑gen liquid‑biopsy tests, driving growth in the $26 bn genomic diagnostics market.

Read Natera’s latest SEC filing: a senior officer sold shares on May 1, 2026, highlighting the company’s equity‑compensation strategy and its impact on shareholder confidence and corporate governance.

Insightful analysis of Natera’s insider trades shows routine Rule 144/10b‑5‑1 filings, minimal financial impact, and strong governance signals for investors.

Discover how Natera’s Signatera ctDNA test is reshaping bladder‑cancer care with MRD‑guided therapy, market insights, and ASCO presentation highlights.